Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2010

01-08-2010 | Case Report

Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy

Authors: Tomoko Namba, Rie Shiba, Takeshi Yamamoto, Yasuhiro Hirai, Takuma Moriwaki, Jun Matsuda, Hiroyuki Kadoya, Masanobu Takeji, Yukinori Yamada, Harumasa Yoshihara, Atsushi Yamauchi

Published in: Clinical and Experimental Nephrology | Issue 4/2010

Login to get access

Abstract

A 67-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital because of proteinuria and leg edema. Laboratory examination showed decreased serum albumin and complement activity and positive cryoglobulin. The HCV RNA genotype was 1b with high viral load. Kidney biopsy showed membranoproliferative glomerulonephritis (MPGN) with capillary deposition of C3, IgM, and IgG, indicating HCV-associated glomerulonephritis. In addition to interferon (IFN) therapy, double-filtration plasmapheresis (DFPP) was performed to reduce HCV RNA blood levels in the early stage of IFN therapy. This treatment greatly reduced the viral load and induced clinical remission of MPGN, suggesting that DFPP plus IFN combination therapy may represent a potentially effective modality for refractory-type HCV-associated glomerulonephritis.
Literature
1.
go back to reference Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46:1255–63.CrossRefPubMed Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46:1255–63.CrossRefPubMed
2.
go back to reference Dagestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347–54.CrossRef Dagestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347–54.CrossRef
3.
go back to reference Willson RA. The benefit of long-term interferon-alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection. J Clin Gastroenterol. 2001;33:137–40.CrossRefPubMed Willson RA. The benefit of long-term interferon-alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection. J Clin Gastroenterol. 2001;33:137–40.CrossRefPubMed
4.
go back to reference Pham HP, Feray C, Samuel D, Gigou M, Azoulay D, Paradis V, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipient. Kidney Int. 1998;54:1311–9.CrossRefPubMed Pham HP, Feray C, Samuel D, Gigou M, Azoulay D, Paradis V, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipient. Kidney Int. 1998;54:1311–9.CrossRefPubMed
5.
go back to reference Garini G, Allegri L, Carnevali L, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis. 2001;38:1–5.CrossRef Garini G, Allegri L, Carnevali L, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis. 2001;38:1–5.CrossRef
6.
go back to reference Perico N, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207–20.CrossRefPubMed Perico N, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207–20.CrossRefPubMed
7.
go back to reference Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37:701–10.CrossRefPubMed Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37:701–10.CrossRefPubMed
8.
go back to reference Takada Y, Ito T, Ueda Y, Haga H, Egawa H, Tanaka K, et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transplant. 2008;14:1044–7.CrossRef Takada Y, Ito T, Ueda Y, Haga H, Egawa H, Tanaka K, et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transplant. 2008;14:1044–7.CrossRef
9.
go back to reference The Guideline Development Work Group and the Evidence Review Team. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Guideline 2: treatment of HCV infection in patients with CKD. Kidney Int. 2008;73:S20–45.CrossRef The Guideline Development Work Group and the Evidence Review Team. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Guideline 2: treatment of HCV infection in patients with CKD. Kidney Int. 2008;73:S20–45.CrossRef
10.
go back to reference Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int. 2006;69:436–9.CrossRefPubMed Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int. 2006;69:436–9.CrossRefPubMed
11.
go back to reference Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151–6.PubMed Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151–6.PubMed
12.
go back to reference Fabrizi F, Martin P, Dixit Y, Brezina M, Cole MJ, Vinson S, et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis. 2000;35:122–9.CrossRefPubMed Fabrizi F, Martin P, Dixit Y, Brezina M, Cole MJ, Vinson S, et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis. 2000;35:122–9.CrossRefPubMed
13.
go back to reference Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354:1782–5.CrossRefPubMed Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354:1782–5.CrossRefPubMed
14.
go back to reference Schettler V, Monazahian M, Wieland E, et al. Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Invest. 2001;31:154–5.CrossRefPubMed Schettler V, Monazahian M, Wieland E, et al. Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Invest. 2001;31:154–5.CrossRefPubMed
15.
go back to reference Diepolder HM, Kashiwagi N, Teuber G, Ulsenheimer A, Franz M, Yokoyama T, et al. Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1. J Med Virol. 2005;77:209–15.CrossRefPubMed Diepolder HM, Kashiwagi N, Teuber G, Ulsenheimer A, Franz M, Yokoyama T, et al. Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1. J Med Virol. 2005;77:209–15.CrossRefPubMed
16.
go back to reference Sawada K, Masaki N, Hayashi S, Zeniya M, Ishikawa T, Takahashi H, et al. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-α2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia. J Viral Hepat. 2005;12:274–82.CrossRefPubMed Sawada K, Masaki N, Hayashi S, Zeniya M, Ishikawa T, Takahashi H, et al. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-α2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia. J Viral Hepat. 2005;12:274–82.CrossRefPubMed
17.
go back to reference Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res. 2006;36:167–75.CrossRefPubMed Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res. 2006;36:167–75.CrossRefPubMed
18.
Metadata
Title
Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy
Authors
Tomoko Namba
Rie Shiba
Takeshi Yamamoto
Yasuhiro Hirai
Takuma Moriwaki
Jun Matsuda
Hiroyuki Kadoya
Masanobu Takeji
Yukinori Yamada
Harumasa Yoshihara
Atsushi Yamauchi
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0282-3

Other articles of this Issue 4/2010

Clinical and Experimental Nephrology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.